Abstract
In vitro immunization (IVI) techniques have a great potential in the production of human monoclonal antibodies (MAbs) against various antigens. An IVI method of human peripheral blood lymphocytes (PBL) has been developed with a human lung adenocarcinoma cell line in our laboratory. Although several cancer specific human MAbs were successfully generated by using this IVI method, it was not available for soluble antigens, which prompted us to improve the method for generation of human MAbs against soluble antigens. IVI with soluble antigens was effectively caused by the addition of muramyl dipeptides, interleukin-2 and interleukin-4. It was found that the difference of sensitivity of lymphocytes depending upon donors could be overcome by finding the optimal concentrations of IL-2 and IL-4. IVI of human PBL was performed with cholera toxin B subunit (CTB) and the immunized B cells were transformed by Epstein-Barr virus. Anti-CTB antibody was detected using an indirect ELISA. B cells producing anti-CTB antibodies were directly cloned by a soft agar cloning method.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexander H, Harpprecht J, Podzuweit HG, Rautenberg P and Müller-Ruchholtz W (1994) Human monoclonal antibodies recognize early and late viral proteins of human cytomegalovirus. Hum Antibod Hybridomas 5: 81–90.
Alfonso M, Lanne B, Ifversen P, Vázquez AM, Pérez R, Portoukalian J and Zeuthen J (1995) Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside. Hum Antibod Hybridomas 6: 102–112.
Borrebaeck CAK (1989) Strategy for the production of monoclonal antibodies using in vitro activated B-cells. J Immunol Methods 123: 157–165.
Boyd AW, Fisher DC, Fox DA Schlossman SF and Nadler LM (1985) Structural and functional characterization of IL-2 receptors on activated human B cells. J Immunol 134: 2387–2392.
Defrance T, Vanbervliet B, Aubry JP, Takabe Y, Arai N, Miyajima A, Yokota T, Lee F and Arai KI (1987) B cell growth-promoting activity of recombinant human interleukin 4. J Immunol 139: 1135–1141.
Defrance T, Vanbervliet B, Pene J and Banchereau J (1988) Human recombinant IL-4 induces activated B lymphocytes to produce IgG and IgM. J Immunol 141: 2000–2005.
Glassy MC (1993) Production methods for generating human monoclonal antibodies. Hum Antibod Hybridomas 4: 154–165.
Gupta KC, Agha R, Santos E and Brodeur BR (1992) Isolation of human monoclonal antibodies binding to B fragment of diphtheria toxin. Hum Antibod Hybridomas 3: 25–31.
Hoffmann P, Jimenez-Diaz M, Loleit M, Tröger W, Wiesmüller KH, Metzger J, Jung G, Kaiser I, Stöcklin S, Lenzner S, Peters JH, Grimm R, Schäfer E and Bessler WG (1990) Preparation of human and murine monoclonal antibodies: antigens combined with or conjugated to lipopeptides constitute potent immunogens for in vitro and in vivo immunizations. Hum Antibod Hybridomas 1: 137–144.
James K and Bell TG (1987) Human monoclonal antibody production. J Immunol Methods 100: 5–40.
Jelinek DF and Lipsky PE (1987) Comparative activation requirements of human peripheral blood, spleen, and lymph node B cells. J Immunol 139: 1005–1013.
Kawahara H, Shirahata S, Tachibana H and Murakami H (1992) In vitro immunization of human lymphocytes with human lung cancer cell line A549. Hum Antibod Hybridomas 3: 8–13.
Koda K and Glassy MC (1990) In vitro immunization for the production of human monoclonal antibody. Hum Antibod Hybridomas 1: 15–22.
Laroche-Traineau J, Clofent-Sanchez, Venzon G and Nurden AT (1994) The ex vivo production of human monoclonal antibodies to glycoprotein IIb-IIIa complexes of Blood platelets. Hum Antibod Hybridomas 5: 165–177.
Paul WE and Ohara J (1987) B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol 5: 429–459.
Power DA, Gerkis V and d'Apice AJF (1990) Production of human monoclonal antibodies to B lymphocyte cell surface antigens by in vitro immunization and human-human hybridoma technology. Hum Antibod Hybridomas 1: 34–41.
Sahasrabuddhe GC, Martin BA and Davis FM (1988) Immunological evidence for the relation between low Mr secreted form of human B cell growth factor and an intracellular 60K proteins. Lymphokine Res 7: 141–155.
Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, Melvin DB, Penn I, Ballistreri WF and Alexander JW (1990) Antimurine antibody formation following OKT3 therapy. Transplantation 49: 48–51.
Shoji M, Kawamoto S, Sato S, Kamei M, Kato M, Hashizume S, Seki K, Yasumoto K, Nagashima A, Nakanishi H, Suzuki T, Imai T., Nomoto K and Murakami H (1994a) Specific reactivity of human monoclonal antibody AE6F4 against cancer cells in tissues and sputa from lung cancer patients. Hum Antibod Hybridomas 5: 116–122.
Shoji M, Kawamoto S, Setoguchi Y, Mochizuki K, Honjoh T, Kato M, Hashizume S, Hanagiri T, Yoshimatsu T, Nakanishi K, Yasumoto K, Nagashima A, Nakahashi H, Suzuki T, Imai T, Nomoto K and Murakami H (1994b) The 14–3–3 protein as the antigen for lung cancer-associated human monoclonal antibody AE6F4. Hum Antibod Hybridomas 5: 123–130.
Yokota T, Arai N, deVries J, Spits H, Banchereau J, Zlotnik A, Rennick D, Howard M, Takabe Y, Miyatake S, Lee F and Arai KI (1988) Molecular biology of interleukin 4 and interleukin 5 gene and biology of their products that stimulate B cells, T cells and hematopoietic cells. Immunol Rev 102: 137–187.
Rights and permissions
About this article
Cite this article
Ichikawa, A., Katakura, Y., Teruya, K. et al. In vitro immunization of human peripheral blood lymphocytes: establishment of B cell lines secreting IgM specific for cholera toxin B subunit from lymphocytes stimulated with IL-2 and IL-4. Cytotechnology 31, 133–141 (1999). https://doi.org/10.1023/A:1008063903946
Issue Date:
DOI: https://doi.org/10.1023/A:1008063903946